Findings published from phase III trial of patients with moderate-to-severe acute postoperative pain
THURSDAY, July 11, 2019 (HealthDay News) — Oliceridine is being proposed as an analgesic option for the relief of moderate-to-severe acute postoperative pain, according to a study recently published in Pain Practice.
Neil K. Singla, M.D., from Lotus Clinical Research in Pasadena, California, and colleagues randomly assigned 401 patients with moderate-to-severe acute postoperative pain following abdominoplasty to a loading dose of either placebo, oliceridine (1.5 mg), or morphine (4 mg), followed by demand doses administered through patient-controlled analgesia (0.1, 0.35, or 0.5 mg oliceridine; 1 mg morphine; or placebo) with a six-minute lockout interval.
The researchers found that effective analgesia was achieved with all oliceridine regimens, with responder rates of 61.0 percent for the 0.1-mg demand dose regimen, 76.3 percent for the 0.35-mg regimen, and 70.0 percent for the 0.5-mg regimen, versus 45.7 percent for placebo and 78.3 percent for morphine. Equivalent analgesic effect was seen for oliceridine 0.35- and 0.5-mg regimens, compared to morphine. The respiratory safety burden (RSB) demonstrated a dose-dependent increase across oliceridine regimens (mean hours, 0.1 mg: 0.43; 0.35 mg: 1.48; 0.5 mg: 1.59, compared to placebo [0.60]; the RSB measure for morphine was 1.72). There was also a dose-dependent increase in gastrointestinal adverse events across oliceridine demand dose regimens (0.1 mg: 49.4 percent; 0.35 mg: 65.8 percent; 0.5 mg: 78.8 percent, compared to placebo [47.0 percent] and morphine [79.3 percent]). However, the proportion of patients experiencing nausea or vomiting was lower with 0.35 and 0.5 mg oliceridine versus morphine.
“These findings support that oliceridine may provide a new treatment option for patients with moderate-to-severe acute pain where an intravenous opioid is warranted,” the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Trevena, which manufactures oliceridine and sponsored the study.
Mindfulness, Tai Chi May Benefit Cancer Survivors 
Less Intraoperative Crystalloid Fluid Not Tied to Worse Surgical Outcomes 
Blinatumomab Improves Event-Free Survival in Children With High-Risk B-Cell ALL 
Intrauterine Instillation of Mepivacaine Reduces Pain of IUD Placement 
Socioeconomic Status Linked to Mortality After Acute Hip Fracture Surgery 
Spinal Cord Stimulation Cuts Pain, Improves Sensation With Diabetic Nerve Damage 
Napping Opportunity May Improve Clinical Performance of Anesthesia Residents 
People Using Illicitly Sourced Fentanyl Face Worse Outcomes Than Medically Sourced Users 
